Cargando…

Baicalin reduces blood lipids and inflammation in patients with coronary artery disease and rheumatoid arthritis: a randomized, double-blind, placebo-controlled trial

BACKGROUND: Patients with rheumatoid arthritis (RA) have an increased risk of coronary artery disease (CAD) above the baseline. Baicalin possesses beneficial effects against both RA and CAD, but little is know on its clincial efficacy among patients manifesting both CAD and RA. METHODS: Three hundre...

Descripción completa

Detalles Bibliográficos
Autores principales: Hang, Yuanxing, Qin, Xian, Ren, Tianli, Cao, Jianing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6015450/
https://www.ncbi.nlm.nih.gov/pubmed/29935544
http://dx.doi.org/10.1186/s12944-018-0797-2
_version_ 1783334415792865280
author Hang, Yuanxing
Qin, Xian
Ren, Tianli
Cao, Jianing
author_facet Hang, Yuanxing
Qin, Xian
Ren, Tianli
Cao, Jianing
author_sort Hang, Yuanxing
collection PubMed
description BACKGROUND: Patients with rheumatoid arthritis (RA) have an increased risk of coronary artery disease (CAD) above the baseline. Baicalin possesses beneficial effects against both RA and CAD, but little is know on its clincial efficacy among patients manifesting both CAD and RA. METHODS: Three hundred seventy four patients with CAD and RA were randomized to receive either 500 mg baicalin or placebo orally everyday for 12 weeks. Lipid profile, cardiotrophin-1 (CT-1), high sensitivity C-reactive protein (hs-CRP), European League Against Rheumatism (EULAR) response were analyzed at the end of study period. RESULTS: After 12 week treatment, levels of triglycerides, total cholesterol, LDL-cholesterol and apolipoproteins, as well as CT-1 and hs-CRP, were all significantly improved in the baicalin group compared to the placebo group (1.12 ± 0.36 vs 1.87 ± 0.46 mmol/L, 2.87 ± 1.23 vs 3.22 ± 1.07 mmol/L, 1.38 ± 0.41 vs 1.16 ± 0.32 mmol/L, 1.31 ± 0.41 vs 1.23 ± 0.29 g/L, 42.9 ± 13.7 vs 128.4 ± 24.3 ng/mL, 1.64 ± 0.38 vs 3.9 ± 1.4 mg/dL, respectively). Significantly higher proportion of patients in the baicalin group (71%) reported good/moderate EULAR response than the placebo group (53%). CONCLUSION: Baicalin reduces blood lipids and inflammation in patients with both CAD and RA, supporting its further clinical application.
format Online
Article
Text
id pubmed-6015450
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-60154502018-07-05 Baicalin reduces blood lipids and inflammation in patients with coronary artery disease and rheumatoid arthritis: a randomized, double-blind, placebo-controlled trial Hang, Yuanxing Qin, Xian Ren, Tianli Cao, Jianing Lipids Health Dis Research BACKGROUND: Patients with rheumatoid arthritis (RA) have an increased risk of coronary artery disease (CAD) above the baseline. Baicalin possesses beneficial effects against both RA and CAD, but little is know on its clincial efficacy among patients manifesting both CAD and RA. METHODS: Three hundred seventy four patients with CAD and RA were randomized to receive either 500 mg baicalin or placebo orally everyday for 12 weeks. Lipid profile, cardiotrophin-1 (CT-1), high sensitivity C-reactive protein (hs-CRP), European League Against Rheumatism (EULAR) response were analyzed at the end of study period. RESULTS: After 12 week treatment, levels of triglycerides, total cholesterol, LDL-cholesterol and apolipoproteins, as well as CT-1 and hs-CRP, were all significantly improved in the baicalin group compared to the placebo group (1.12 ± 0.36 vs 1.87 ± 0.46 mmol/L, 2.87 ± 1.23 vs 3.22 ± 1.07 mmol/L, 1.38 ± 0.41 vs 1.16 ± 0.32 mmol/L, 1.31 ± 0.41 vs 1.23 ± 0.29 g/L, 42.9 ± 13.7 vs 128.4 ± 24.3 ng/mL, 1.64 ± 0.38 vs 3.9 ± 1.4 mg/dL, respectively). Significantly higher proportion of patients in the baicalin group (71%) reported good/moderate EULAR response than the placebo group (53%). CONCLUSION: Baicalin reduces blood lipids and inflammation in patients with both CAD and RA, supporting its further clinical application. BioMed Central 2018-06-23 /pmc/articles/PMC6015450/ /pubmed/29935544 http://dx.doi.org/10.1186/s12944-018-0797-2 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Hang, Yuanxing
Qin, Xian
Ren, Tianli
Cao, Jianing
Baicalin reduces blood lipids and inflammation in patients with coronary artery disease and rheumatoid arthritis: a randomized, double-blind, placebo-controlled trial
title Baicalin reduces blood lipids and inflammation in patients with coronary artery disease and rheumatoid arthritis: a randomized, double-blind, placebo-controlled trial
title_full Baicalin reduces blood lipids and inflammation in patients with coronary artery disease and rheumatoid arthritis: a randomized, double-blind, placebo-controlled trial
title_fullStr Baicalin reduces blood lipids and inflammation in patients with coronary artery disease and rheumatoid arthritis: a randomized, double-blind, placebo-controlled trial
title_full_unstemmed Baicalin reduces blood lipids and inflammation in patients with coronary artery disease and rheumatoid arthritis: a randomized, double-blind, placebo-controlled trial
title_short Baicalin reduces blood lipids and inflammation in patients with coronary artery disease and rheumatoid arthritis: a randomized, double-blind, placebo-controlled trial
title_sort baicalin reduces blood lipids and inflammation in patients with coronary artery disease and rheumatoid arthritis: a randomized, double-blind, placebo-controlled trial
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6015450/
https://www.ncbi.nlm.nih.gov/pubmed/29935544
http://dx.doi.org/10.1186/s12944-018-0797-2
work_keys_str_mv AT hangyuanxing baicalinreducesbloodlipidsandinflammationinpatientswithcoronaryarterydiseaseandrheumatoidarthritisarandomizeddoubleblindplacebocontrolledtrial
AT qinxian baicalinreducesbloodlipidsandinflammationinpatientswithcoronaryarterydiseaseandrheumatoidarthritisarandomizeddoubleblindplacebocontrolledtrial
AT rentianli baicalinreducesbloodlipidsandinflammationinpatientswithcoronaryarterydiseaseandrheumatoidarthritisarandomizeddoubleblindplacebocontrolledtrial
AT caojianing baicalinreducesbloodlipidsandinflammationinpatientswithcoronaryarterydiseaseandrheumatoidarthritisarandomizeddoubleblindplacebocontrolledtrial